Repositório Digital

A- A A+

Seriam as apolipoproteinas A e B mais eficientes do que as lipoproteinas na investigacao de risco de doenca arterial coronariana obstrutiva?

.

Seriam as apolipoproteinas A e B mais eficientes do que as lipoproteinas na investigacao de risco de doenca arterial coronariana obstrutiva?

Mostrar registro completo

Estatísticas

Título Seriam as apolipoproteinas A e B mais eficientes do que as lipoproteinas na investigacao de risco de doenca arterial coronariana obstrutiva?
Outro título Are apolipoproteins A and B better than lipoproteins for assessing risk of obstructive coronary heart disease?
Autor Manfroi, Waldomiro Carlos
Zago, Alcides José
Alves, Alexandre
Brisolara, Maria Lucia
Souza, Josiane de
Candiago, Rafael Henriques
Kirschnick, Luciana Schmidt
Ribeiro, Leticia Carina
Ordovas, Karen Gomes
Leitão, Cristiane Bauermann
Cruz, Rosana
Abstract Objective – To evaluate whether apolipoproteins A-I (Apo A-I) and B (Apo B) have, higher ensitivity (SN), specificity (SP) and positive predictive value (PPV) than lipoproteins (LP), total cholesterol (TC), high density lipoprotein (HDL), low density lipoprotein (LDL), very low density lipoprotein (VLDL), and triglycerides (TGL) in assessing the risk of coronary heart disease (CHD). Methods – This is a transversal case-control study of 241 patients, who were divided into two groups: 1) 145 patients with CHD, and 2) 96 patients without coronary disease. A model of logistic regression to evaluate the relation between the LPs and CHD was developed in which variables with a p-alpha <0.1 were included. Results – Apo A-I levels were higher in the patients without CHD, (OR 2.08, CI 1.20-3.57). There were no statistical differences between the values of Apo A-I and the remaining lipid fractions (Apo A-I: 67%; Apo B: 100%; PPV: TC= 71%; TGC=71%; HDL=71%; LDL=71%). The costs of the tests in Reais were as follows: Apo A-I: R$ 56.60; Apo B-100: R$ 56.60; TC: R$ 9.94; HDL: R$ 21.30; LDL: R$ 28.40; TGL: R$ 14.20. Conclusion – Levels of Apo A-I and Apo B have no advantage over conventional lipoproteins in predicting the risk of CHD, despite the statistical association between Apo A-I and CHD; in addition, their costs are higher than those of the conventional lipoproteins.
Contido em Arquivos Brasileiros de Cardiologia. Sao Paulo. vol. 72, n. 6 (1999), p. 657-662
Assunto Arteriopatias oclusivas
Estudo comparativo
Fatores de risco
Lipoproteinas
[en] Coronary heart disease
[en] Lipoproteins
[en] Risk factors
Origem Nacional
Tipo Artigo de periódico
URI http://hdl.handle.net/10183/19306
Arquivos Descrição Formato
000242565.pdf (46.10Kb) Texto completo (inglês) Adobe PDF Visualizar/abrir

Este item está licenciado na Creative Commons License

Este item aparece na(s) seguinte(s) coleção(ões)


Mostrar registro completo

Percorrer



  • O autor é titular dos direitos autorais dos documentos disponíveis neste repositório e é vedada, nos termos da lei, a comercialização de qualquer espécie sem sua autorização prévia.
    Projeto gráfico elaborado pelo Caixola - Clube de Criação Fabico/UFRGS Powered by DSpace software, Version 1.8.1.